Vivet Therapeutics Secures EUR 4.9 Million to Progress Development of Gene Therapy Targeting Cerebrotendinous Xanthomatosis
Vivet Therapeutics Secures EUR 4.9 Million Government Funding for Gene Therapy Advancement in Cerebrotendinous Xanthomatosis Treatment” Vivet Therapeutics, a biotech company specializing in gene therapies for rare inherited metabolic disorders,…
Merck Inaugurates Its Maiden Digital Hub in Singapore
Merck Unveils First Digital Hub in Singapore, a Landmark Move Beyond the US and Europe In a strategic move, Merck, a leading science and technology company, has inaugurated its inaugural…
Newly Elected Board Members at E. Merck KG
E. Merck KG Announces Results of Board Election E. Merck KG, the entity holding approximately 70 percent of Merck KGaA on behalf of the Merck family, revealed the outcomes of…
Regeneron Establishes Regeneron Cell Medicines Through Acquisition of 2seventy Bio Platforms and Development Programs
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the establishment of Regeneron Cell Medicines, marking a strategic agreement with 2seventy bio, Inc. to acquire complete development and commercialization rights to its…
FDA Approves Kite’s Manufacturing Process Change, Leading to Faster Turnaround Time for Yescarta CAR T-cell Therapy
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene…
Gilead and Arcus Revise Collaboration Agreement and Equity Investment Terms
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced an amendment to their collaboration agreement, along with a separate equity investment by Gilead of $320 million…
Vertex Reports Favorable Outcomes from Phase 3 Trials of VX-548 for Managing Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has reported positive outcomes from its Phase 3 program for VX-548, a selective NaV1.8 inhibitor, designed to address moderate-to-severe acute pain. The Phase 3 program…
Bristol Myers Squibb’s Breyanzi Granted Regulatory Acceptance in the U.S. and Japan for Relapsed or Refractory Follicular Lymphoma and Relapsed or Refractory Mantle Cell Lymphoma
Bristol Myers Squibb (NYSE: BMY) has received regulatory acceptance from both the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) for Breyanzi® (lisocabtagene…
Sanofi Achieves Robust Sales and Business EPS Growth at Constant Exchange Rates, Fueled by Successful Product Launches and Progress in Immunology Pipeline
In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth…
Priority Review Granted in the US for Enhertu in Patients with Metastatic HER2-Positive Solid Tumors
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the…
Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO) Demonstrated by Roche’s Vabysmo
Roche (SIX: RO, ROG; OTCQX: RHHBY) has disclosed compelling 72-week data derived from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in the treatment of macular edema…
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
Novo Nordisk’s sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023 PROFIT AND LOSS 2023 2022 Growthas reported Growthat…